Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PTOI attracts NON-batshit "PEREGRINES" with Bordynuik's GUMMY-BEARS?
What are your thoughts about this?
AHHHHHHHHHHHHHH!!!!!!!!! AHHHHHHHHHHHHHHHHHHHHH!!!!!!!!!!!!!!!!
WOW! WOW! WOW!
AAAAAAAAAAAAAAAHHHHHHHHHHHHHHHHH!!!!!!!!!!!!!!!!!!
Both statements are bullshit.
The truth is:
1). NNVC has NEVER submitted an IND to the FDA for anything in its 16 years of scamming the public,
2) The NIH has NEVER given a single penny to NNVC.
Here are a very small number of the lies that Nanoviricides have announced in PRs over the last 16 years.
SIXTEEN YEARS OF LIES. They have all turned out to be lies.
NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug
November, 2005
https://www.businesswire.com/news/home/20051107005498/en/NanoViricides-Reports-Initial-Safety-Results-Anti-Influenza-Bird
NanoViricides, Inc. to Tackle Asian Bird Flu
10/3/2005
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165482267
Novel Influenza and Bird Flu Therapeutics Moving Rapidly at NanoViricides, Inc. September, 2007
https://www.businesswire.com/news/home/20070904005487/en/Influenza-Bird-Flu-Therapeutics-Moving-Rapidly-NanoViricides
NanoViricides is on Course to Develop Bird Flu, Influenza, and Other Drugs January, 2008.
https://www.businesswire.com/news/home/20080122005644/en/NanoViricides-Develop-Bird-Flu-Influenza-Drugs
NanoViricides, Inc. Release: Anti-Dengue NanoViricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever [/b]June, 2010
https://www.biospace.com/article/releases/nanoviricides-inc-release-anti-dengue-nanoviricides-achieve-significant-protection-in-initial-in-vivo-studies-on-dengue-hemorrhagic-fever-/
NanoViricides Reports That Oral Administration of FluCide®, its Anti-Influenza Drug Candidate Was Effective In Animal Model. Aug 13, 2012
https://www.fiercepharma.com/pharma/nanoviricides-reports-oral-administration-of-flucide®-its-anti-influenza-drug-candidate-was
NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency November, 2013
http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20DengueCide%E2%84%A2%20Has%20Received%20Orphan%20Drug%20Designation%20From%20the%20European%20Medicines%20Agency%20(EMA).html
NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference June, 2014
https://www.businesswire.com/news/home/20140714005478/en/NanoViricides-President-Dr.-Diwan-Presented-FluCide-Data
NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates September, 2014
http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html
NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model April 2015
https://www.biospace.com/article/releases/nanoviricides-inc-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model-/
NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruse June 2016
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology October, 2017
http://www.nanoviricides.com/press%20releases/2017/NanoViricides%20to%20Present%20Results%20On%20Successful%20Treatment%20Of%20Herpes-Induced%20Acute%20Retinal%20Necrosis%20at%20the%20Annual%20Meeting.html
NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials May,2018
https://www.biospace.com/article/releases/nanoviricides-provides-update-says-company-is-stable-and-is-moving-steadily-towards-clinical-trials/?s=86
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials Feb, 2019
https://www.accesswire.com/567044/NanoViricides-Files-Quarterly-Report-for-Period-Ending-September-30-2019--HerpeCide-Drug-Candidate-IND-Enabling-Studies-Update-Progressing-Towards-Clinical-Trials
NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses. May 12, 2020
https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/stock-news/82433957/nanoviricides-develops-highly-effective-broad-spec
But maybe Nanoviricides is lying in their PRs.
What if NNVC is lying in these PRs?
In just one year of doubling your money daily, you could start with $0.01 on Day-1, and by Day-365 have:
$75,153,362,648,762,663,296,604,840,226,240,804,240,800,822,062,466,648,224,284,448,402,846,248,028,800,660,488,824,646,222,862,868,044,242,442,222.00
I know how to do that.
Volume: 200
200 BLOODY SHARES!!!
WHO THE HELL BOUGHT THE 200 BLOODY SHARES?
FOR $4.00.
HMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM?
Plastic2Oil Inc (PK) (PTOI)
0.0168 ? -0.00295 (-14.94%)
Volume: 200 @10/06/21 3:44:59 PM EDT
Bid Ask Day's Range
0.0155 0.023 0.0168 - 0.0199
Sounds like it’s time to invest every penny in this cream puff!
If someone lies about it working in rats, then it'll work in humans.
If you say so!
The P2O BAT-SHIT Documentor could confirm or refute this.
never dull ..
Volume: 1
ONE BLOODY SHARE!!!
WHO THE HELL BOUGHT THE ONE BLOODY SHARE?
HMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM?
Plastic2Oil Inc (PK) (PTOI)
0.01975 ? 0.0 (0.00%)
Volume: 1 @10/05/21 12:14:36 PM EDT
“Required GLP Safety/Toxicology Studies of NV-CoV-2 Completed”
Assuming they can say the same thing for the required CMC work, there’s absolutely nothing stopping them from submitting an IND application and starting Phase-1 studies before end of year.
If I were given 15 minutes to present to investors, that would be the one point I’d emphasize. It’s the one milestone that would put them ahead of the hundreds of micrcrap biowrecks heading nowhere.
But it’s not even on the the list of ten “presentation highlights”.
If you say so!
If you say so!
It's as if Mr. Brain suffers from some type of psychiatric disorder that compels him be be a chronic sap.
Lord knows how he explains his financial losses to his family.
Here's what the Tamiflu label says:
"TAMIFLU is a prescription medicine used to treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than 2 days. "
https://www.tamiflu.com/
Here's what Merk says about Molnupiravir:
" Eligibility criteria required that all patients had laboratory-confirmed mild-to-moderate COVID-19, with symptom onset within 5 days of study randomization. All patients were required to have at least one risk factor associated with poor disease outcome at study entry. Molnupiravir reduced the risk of hospitalization and/or death across all key subgroups; efficacy was not affected by timing of symptom onset or underlying risk factor. Additionally, based on the participants with available viral sequencing data (approximately 40% of participants), molnupiravir demonstrated consistent efficacy across viral variants Gamma, Delta, and Mu.
The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Similarly, the incidence of drug-related adverse events was also comparable (12% and 11%, respectively). Fewer subjects discontinued study therapy due to an adverse event in the molnupiravir group (1.3%) compared to the placebo group (3.4%). "
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
NEWS -- Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment
https://www.statnews.com/2021/10/01/mercks-antiviral-pill-reduces-hospitalization-of-covid-patients-a-possible-game-changer-for-treatment/
NEWS -- Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment
https://www.statnews.com/2021/10/01/mercks-antiviral-pill-reduces-hospitalization-of-covid-patients-a-possible-game-changer-for-treatment/
P2O has been a nonoperational shell for the past seven years, and remains so:
"We shut down our fuel production late in the fourth quarter of 2013 due to severe cold weather that caused damage to condensers and other components of our processors and we have not resumed fuel production due to the repair costs as well as our shift in strategy toward manufacturing processors for sale, as opposed to producing and selling fuel products. Management estimates that the repair of the processors will require the expenditure of between $275,000 and $300,000. An additional $500,000 of startup working capital will be required to resume operations..."
Where is the mention of the 9.9 billion reasons for something or other?
Maybe that needs to be included to get his attention.
Any updates?
We could use some *documentation* about now to lighten things up around here ;)
We’re not giving up just because Heddle ignored ONE email, are we?
Try the same thing with Lee Brain. He was an investor posting here before he became a director, so you might have more luck getting a reply:
email: lee@hessmillwork.com
Phone: (905) 777-0438
You might even remind him of the his own words that he wrote before he became a director, and ask him to explain what became of it, especially with respect to the highlighted part below:
Lee Brain 2014:
"JBI is indeed still a startup company. When I started my business many years ago, more than one person who had done the same before me, told me not to expect to turn a profit for 5 years. I worked my ass off....HARD PHYSICAL LABOUR!!! I didn't take home very much money. I persevered! Now I sit behind a desk making 7 digits. I have a very simple business, nothing compared to what JBI has going on in NF NY. John has persevered. Success is not only just around the corner, but it has already happened......just waiting for the rewards!
As I've said a couple of times before, JBI will not go under due to lack of funding. As long as the technology keeps advancing....as long as processor # 3 does what it is designed to do,the money is there. I have access to tens of millions of investment dollars that would not dilute the share structure.
I'm not the only one that has access to funds. Rick Heddle completes contract repairers for shipping companies, do you know what kind of money is in the shipping business? Remember Aristotle Onassis?......Billionaire before billionaire's were very common (I personally know two billionaire's)
THE MONEY IS NOT AN ISSUE IF THE TECHNOLOGY IS THERE! "
The must explain why he shut down P2O seven years ago, and hasn’t done anything with the company since!
“NanoViricides is scheduled to present a talk on “How to keep a micrcrap scam going for 16+ years, make $120,000,000 vanish, while creating generational wealth for your family”.
“For short positions in stock where the last sale price/share is less than $5, then the maintenance margin requirement is $2.50 per share or 100% of the stock value, whichever is greater.”
https://ibkr.info/node/285
These shit-stocks are volatile. One bullshit PR can cause it to double premarket, triggering automatic margin covers.
The $2,50/share margin requirements and high risk of losing everything is why no sane retail investor actually shorts penny stocks, regardless of how much of a “sure thing” it is.
Yet Heddle already shut it down 7yrs ago, and hasn't done anything since.
A bit of cognitive dissonance here, yes?
If only someone would communicate this to Heddle.
Then the company would be saved and all shareholders would recover their lost investments.
But alas...
It must mean that longs don't really want P2O to succeed.
Maybe Heddle is competing with
The League of Attention-Seeking Obtuse BAT-SHITTERS to see if he can get his spastic lobotomized contender to win the annual Internet Crap-Flood Contest.
I think there's another underappreciated aspect to dead-shell stock scams like P2O ...
They appeal to folks with serious psychiatric illness.
Bordynuik, the inventor of the "technology", dumped all his stock and jumped ship a decade ago. Never mind his track record of fraud.
That alone would be clue enough for anyone who wasn't suffering from delusional psychosis or a botched lobotomy.
P2O ARITHMETIC
Value of working an 8hr shift at MacDonalds: 6,000 P2O shares
Value of screeching like a BAT-SHIT lobotomized chimpanzee for 8hr: 0 P2O shares